Q: What is Kadcyla used for?

Kadcyla is used to treat HER2-positive breast cancer .

Q: How does Kadcyla work?

Targeted Delivery Kadcyla is an antibody-drug conjugate, which means it acts as a delivery system for chemotherapy. It is made of two main components: an antibody called trastuzumab and a chemotherapy drug called emtansine (DM1). These components are joined by a linker that keeps them together until they reach their target. Mechanism of Action The medication works through the following steps to identify and destroy specific cancer cells: Identification: The antibody portion of Kadcyla is designed to seek out and attach to HER2 receptors, which are proteins found in large amounts on the surface of certain cancer cells. Internalization: After Kadcyla attaches to the HER2 receptor, the cancer cell absorbs the entire drug. Activation: Once inside the cell, the chemotherapy (emtansine) is released. It works by disrupting the cell's microtubules, which are structures necessary for the cell to divide and grow. Cell Death: By preventing cell division, the chemotherapy causes the cancer cell to die. In addition to delivering chemotherapy, the trastuzumab portion of the drug may also help the body's immune system identify and attack the cancer cells while blocking signals that tell the cancer to grow. By targeting cells with high levels of HER2, Kadcyla is designed to limit the amount of chemotherapy that reaches healthy cells.

Q: What are the active ingredients in Kadcyla?

The active ingredient in Kadcyla is trastuzumab .

Q: What are the side effects of Kadcyla?

Common side effects of Kadcyla may include: Fatigue Nausea Musculoskeletal pain and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Kadcyla?

Kadcyla belongs to the antibody-drug conjugate drug class.

Q: What is the dosage of Kadcyla and how do I take it?

How Kadcyla is Administered Kadcyla is given as an infusion into a vein by a healthcare provider in a medical setting, such as a hospital or infusion center. It is not available as a pill and cannot be self-administered at home. Treatment Schedule This medication is generally administered in cycles. A common treatment plan involves receiving one infusion every three weeks. Your healthcare provider will determine the total number of cycles based on your specific diagnosis and how your body responds to the therapy. Infusion Duration The initial infusion is usually given slowly so that healthcare providers can monitor you for any immediate reactions. If you tolerate the first dose well, future infusions may be administered over a shorter period of time. Missed Doses If you miss a scheduled appointment for your infusion, you should contact your healthcare provider as soon as possible to reschedule. It is important to maintain the prescribed treatment interval. When a dose is delayed, your doctor will adjust the timing of your subsequent doses to ensure the correct schedule is followed. Important Considerations Kadcyla (ado-trastuzumab emtansine) is a unique medication and is not interchangeable with other trastuzumab products. Your medical team will verify the specific medication before administration to prevent medication errors.

Q: Is Kadcyla safe during pregnancy and breastfeeding?

Pregnancy Kadcyla can cause fetal harm or death when administered to a pregnant woman. Clinical data indicates that exposure to this medication during pregnancy can lead to oligohydramnios, a condition where there is too little amniotic fluid. This can result in life-threatening complications for the fetus, including underdeveloped lungs and skeletal deformities. Healthcare providers typically perform a pregnancy test before starting Kadcyla to ensure the patient is not pregnant. Patients of reproductive potential are advised to use effective contraception during treatment and for 7 months after the last dose. If pregnancy occurs during treatment, it is important to notify a doctor immediately. Breastfeeding There is no information on whether Kadcyla is present in human breast milk or its effects on a breastfed infant. Because of the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for 7 months after the final dose. Patients should consult with their healthcare provider to determine the best way to feed their baby during this time.

Q: What is the FDA approval status of Kadcyla?

FDA Approval History The U.S. Food and Drug Administration (FDA) first approved Kadcyla in February 2013. It was initially indicated for patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane chemotherapy. In May 2019, the FDA expanded the approval to include the adjuvant (after surgery) treatment of patients with HER2-positive early breast cancer who have residual invasive disease after receiving neoadjuvant (before surgery) treatment. Boxed Warnings Kadcyla carries Boxed Warnings, the FDA's most serious type of warning, for the following risks: Hepatotoxicity: Serious liver injury, including liver failure and death, has occurred in patients treated with this medication. Liver function should be monitored prior to each dose. Cardiac Toxicity: Treatment may lead to a reduction in left ventricular ejection fraction (LVEF), which can cause heart failure. Embryo-Fetal Toxicity: Exposure to Kadcyla during pregnancy can cause birth defects or fetal death. Patients of reproductive potential should use effective contraception during treatment. Safety Communications and Medication Errors The FDA has issued safety communications regarding potential medication errors due to confusion between Kadcyla (ado-trastuzumab emtansine) and Herceptin (trastuzumab). These two drugs have different dosing schedules and are not interchangeable. The FDA has also monitored reports of interstitial lung disease and pneumonitis through the FDA Adverse Event Reporting System (FAERS) to identify potential new safety information.

Question 1

What is Kadcyla?

Accepted Answer

Kadcyla is a targeted medication known as an antibody-drug conjugate. It consists of a monoclonal antibody linked to a chemotherapy drug, allowing the treatment to specifically identify and bind to certain proteins on the surface of cells.

Once the medication attaches to these proteins, it enters the cell and releases the chemotherapy agent to stop cell growth. This mechanism allows for a more precise delivery of treatment compared to traditional systemic therapies.

Question 2

What is Kadcyla used for?

Accepted Answer

Kadcyla is used to treat HER2-positive breast cancer.

Question 3

How does Kadcyla work?

Accepted Answer

Targeted Delivery

Kadcyla is an antibody-drug conjugate, which means it acts as a delivery system for chemotherapy. It is made of two main components: an antibody called trastuzumab and a chemotherapy drug called emtansine (DM1). These components are joined by a linker that keeps them together until they reach their target.

Mechanism of Action

The medication works through the following steps to identify and destroy specific cancer cells:

Identification: The antibody portion of Kadcyla is designed to seek out and attach to HER2 receptors, which are proteins found in large amounts on the surface of certain cancer cells.
Internalization: After Kadcyla attaches to the HER2 receptor, the cancer cell absorbs the entire drug.
Activation: Once inside the cell, the chemotherapy (emtansine) is released. It works by disrupting the cell's microtubules, which are structures necessary for the cell to divide and grow.
Cell Death: By preventing cell division, the chemotherapy causes the cancer cell to die.

In addition to delivering chemotherapy, the trastuzumab portion of the drug may also help the body's immune system identify and attack the cancer cells while blocking signals that tell the cancer to grow. By targeting cells with high levels of HER2, Kadcyla is designed to limit the amount of chemotherapy that reaches healthy cells.

Question 4

What are the active ingredients in Kadcyla?

Accepted Answer

The active ingredient in Kadcyla is trastuzumab.

Question 5

What are the side effects of Kadcyla?

Accepted Answer

Common side effects of Kadcyla may include:

Fatigue
Nausea
Musculoskeletal pain
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Kadcyla?

Accepted Answer

Kadcyla belongs to the antibody-drug conjugate drug class.

Question 7

What is the dosage of Kadcyla and how do I take it?

Accepted Answer

How Kadcyla is Administered

Kadcyla is given as an infusion into a vein by a healthcare provider in a medical setting, such as a hospital or infusion center. It is not available as a pill and cannot be self-administered at home.

Treatment Schedule

This medication is generally administered in cycles. A common treatment plan involves receiving one infusion every three weeks. Your healthcare provider will determine the total number of cycles based on your specific diagnosis and how your body responds to the therapy.

Infusion Duration

The initial infusion is usually given slowly so that healthcare providers can monitor you for any immediate reactions. If you tolerate the first dose well, future infusions may be administered over a shorter period of time.

Missed Doses

If you miss a scheduled appointment for your infusion, you should contact your healthcare provider as soon as possible to reschedule. It is important to maintain the prescribed treatment interval. When a dose is delayed, your doctor will adjust the timing of your subsequent doses to ensure the correct schedule is followed.

Important Considerations

Kadcyla (ado-trastuzumab emtansine) is a unique medication and is not interchangeable with other trastuzumab products. Your medical team will verify the specific medication before administration to prevent medication errors.

Question 8

Is Kadcyla safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Kadcyla can cause fetal harm or death when administered to a pregnant woman. Clinical data indicates that exposure to this medication during pregnancy can lead to oligohydramnios, a condition where there is too little amniotic fluid. This can result in life-threatening complications for the fetus, including underdeveloped lungs and skeletal deformities.

Healthcare providers typically perform a pregnancy test before starting Kadcyla to ensure the patient is not pregnant. Patients of reproductive potential are advised to use effective contraception during treatment and for 7 months after the last dose. If pregnancy occurs during treatment, it is important to notify a doctor immediately.

Breastfeeding

There is no information on whether Kadcyla is present in human breast milk or its effects on a breastfed infant. Because of the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for 7 months after the final dose. Patients should consult with their healthcare provider to determine the best way to feed their baby during this time.

Question 9

What forms and strengths does Kadcyla come in?

Accepted Answer

Kadcyla is supplied as a sterile, preservative-free lyophilized powder in single-dose vials.

This medication is administered as an intravenous infusion. Before use, the powder must be reconstituted and then diluted by a healthcare professional. It is not designed for other routes of administration, such as an intravenous push or bolus.

It is important to note that Kadcyla (ado-trastuzumab emtansine) is a different medication than trastuzumab and they are not interchangeable.

Question 10

What is the FDA approval status of Kadcyla?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved Kadcyla in February 2013. It was initially indicated for patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane chemotherapy. In May 2019, the FDA expanded the approval to include the adjuvant (after surgery) treatment of patients with HER2-positive early breast cancer who have residual invasive disease after receiving neoadjuvant (before surgery) treatment.

Boxed Warnings

Kadcyla carries Boxed Warnings, the FDA's most serious type of warning, for the following risks:

Hepatotoxicity: Serious liver injury, including liver failure and death, has occurred in patients treated with this medication. Liver function should be monitored prior to each dose.
Cardiac Toxicity: Treatment may lead to a reduction in left ventricular ejection fraction (LVEF), which can cause heart failure.
Embryo-Fetal Toxicity: Exposure to Kadcyla during pregnancy can cause birth defects or fetal death. Patients of reproductive potential should use effective contraception during treatment.

Safety Communications and Medication Errors

The FDA has issued safety communications regarding potential medication errors due to confusion between Kadcyla (ado-trastuzumab emtansine) and Herceptin (trastuzumab). These two drugs have different dosing schedules and are not interchangeable. The FDA has also monitored reports of interstitial lung disease and pneumonitis through the FDA Adverse Event Reporting System (FAERS) to identify potential new safety information.

Question 11

What should I know about Kadcyla and cost?

Accepted Answer

Factors Influencing Cost

The total price of Kadcyla treatment can vary significantly based on several factors. Because it is a specialty biologic medication administered by a healthcare professional, the cost is generally higher than standard prescription drugs.

Weight-Based Dosing: Kadcyla is administered based on a patient's body weight. Larger doses require more medication, which increases the cost per session.
Administration Fees: Since the drug is given as an intravenous infusion, the total cost includes the price of the drug as well as fees for the clinic or hospital, nursing staff, and supplies.
Insurance Coverage: Most insurance plans cover Kadcyla, but out-of-pocket expenses like deductibles and coinsurance will vary. Many insurers require prior authorization before treatment begins.

Financial Support Options

Patients may have access to financial assistance programs to help manage the cost of Kadcyla. These often include:

Copay Cards: The manufacturer may offer programs to help commercially insured patients with their out-of-pocket costs.
Patient Assistance Programs: For those without insurance or who are underinsured, non-profit organizations or the manufacturer may provide the medication at a reduced cost or for free based on financial need.

Currently, there are no lower-cost biosimilar versions of Kadcyla available on the market.

Kadcyla

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Kadcyla

Hospitals.net Disclosure